1. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection 
Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence Lumeng, Paul Y. Kwo 
Clinical Gastroenterology and Hepatology 
Volume 2, Issue 4, Pages (April 2004)
DOI: /S (04)

2. Figure 1
Distribution of patients in group 1 who received long-term treatment with combination therapy. Despite the development of YMDD mutations by sequencing after an average of 2 years of combination therapy in 3 naive HBeAg subjects, none of them had detectable HBV DNA by Digene assay at 3 years and 3 months of combination therapy (15 months after sample collection for sequencing).
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )

3. Figure 2
ALT levels are shown for 13 treatment-naive HBeAg-positive subjects during 48 weeks of therapy with lamivudine and famciclovir. A significant improvement in ALT was seen by week 24 that persisted to week 48.
Clinical Gastroenterology and Hepatology 2004 2, DOI: ( /S (04) )